SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Paimon SpaceX SPV Token (SPCX) offers investors exclusive access to SpaceX's growth potential through a British Virgin Islands Special Purpose Vehicle structure. Each token represents fractional ownership in the underlying SPV that invests in venture capital funds with SpaceX exposure. SPCX provides a unique opportunity to participate in the space industry's leading innovator. The token structure enables global qualified investors to access this premium late-stage venture equity that would typically be unavailable to most. SPCX is deployed on BNB Chain with plans for multi-chain expansion.

Paimon SpaceX SPV Token

Market speculation is intensifying around a potential SpaceX IPO under the ticker SPCX, with community members actively discussing valuation expectations and the potential for spillover momentum into aerospace industry proxies. Investors are heavily focused on the logistical details of the rumored listing timeline and the broader implications for liquidity across the sector.

Tema ETF Trust - Tema Space Innovators ETF

The $NASA ETF is trending as investors rush to gain exposure to the highly anticipated SpaceX IPO through the fund's 10% stake in the private company, alongside other space infrastructure holdings. Community sentiment is overwhelmingly bullish, with retail investors comparing its potential trajectory to other high-volatility space plays and actively discussing the fund's asset growth as a proxy for the broader commercial space economy.

Kura Sushi USA, Inc. engages in the operation of technology enabled Japanese restaurants. It offers a distinctive dining experience by serving authentic Japanese cuisine through engaging revolving sushi service models. The company was founded by Hajime Uba in 2008 and is headquartered in Irvine, CA.

Kura Sushi USA Inc - Ordinary Shares - Class A

Kura Sushi USA is trending as investors debate the impact of potential tariffs and recent volatility, while the community remains divided over its long-term growth versus valuation concerns. Discussions are heavily focused on the stock's historical tendency for sharp swings and the divergence between its rapid unit expansion and recent price performance.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is trending as investors weigh strong earnings and share repurchases against cautious forward guidance, sparking debate over whether the firm's AI-driven Intelligent Agreement Management (IAM) platform can maintain a competitive moat. Community sentiment remains sharply divided between bulls betting on a valuation recovery fueled by solid fundamentals and bears concerned that AI disruption will commoditize the company's core signature services.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending due to heightened investor enthusiasm surrounding its proprietary Nanosecond Pulsed Field Ablation technology, which is being positioned as a potential breakthrough in cardiac and soft tissue treatment. The community is actively discussing the stock's clinical study milestones, aggressive insider buying by company leadership, and potential for a future buyout or strategic partnership.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is trending as the community highlights its role as infrastructure for autonomous on-chain AI agents within the Base ecosystem. Investors are actively discussing the token's accumulation phase, the potential for long-term utility-driven growth, and the ongoing development of its bot capabilities that facilitate on-chain DeFi transactions.

Stubhub Holdings, Inc. provides online ticket selling services. It also provides services for buyers and sellers of tickets for sports, concerts, theater, and other live entertainment events. The company was founded by Eric H. Baker in 2000 and is headquartered in New York, NY.

Stubhub Holdings Inc. - Ordinary Shares - Class A

StubHub

StubHub is trending as investors debate the impact of potential regulatory crackdowns and shifting ticket market dynamics, with significant community discourse focused on whether the stock's recent volatility presents a deep-value opportunity or a long-term risk. Sentiment remains polarized between those monitoring institutional accumulation and those cautious of the company's competitive moats and legal exposure.

The World Collective Oil Reserve (WCOR) is a public-information program built on the Solana blockchain that mirrors the structure and reporting discipline of national strategic petroleum reserves. It applies established supply-security concepts — including import cover, shock response, emergency release protocols, and transparent stock reporting — to an open, permissionless environment. Data published through the program is drawn from public sources, with approximations clearly identified, and reserve records are maintained on-chain to support auditability, traceability, and independent verification. WCOR is presented as an informational and reference framework rather than a financial product, translating the reporting conventions of traditional strategic inventories into a blockchain-native format that any participant can inspect or cite.

World Collective Oil Reserve

WCOR is experiencing a surge in social media attention as investors speculate on its growth potential, though community members remain divided between excitement over recent gains and concerns regarding its status as a high-risk meme coin. Discussion is heavily focused on technical challenges and confusion surrounding the token's availability across different blockchain networks and trading platforms.

Elbit Systems Ltd. engages in the defense and homeland security sector. It develops and supplies airborne, land and naval systems and products for defense, homeland security, and commercial applications. The firm also provides training and support services. The company was founded in 1996 and is headquartered in Haifa, Israel.

Elbit Systems Ltd.

Elbit Systems is capturing significant market attention as investors weigh its robust global order backlog against ongoing geopolitical demand for its specialized defense and surveillance technologies. While some market participants debate the stock's valuation, community discussion is heavily focused on potential new partnerships and the company's critical role in the expanding defense technology sector.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust is currently trending as community discussions remain heavily focused on Bitcoin's broader price volatility, institutional accumulation strategies by major holders, and ongoing geopolitical tensions in the Middle East impacting market sentiment. Investors are actively debating the potential for a breakout toward higher price levels versus concerns over liquidity squeezes and macroeconomic uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth

Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.

ACADIA Pharmaceuticals (NASDAQ:ACAD) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.02). The company had revenue of $268.10 million for...

ACADIA Pharmaceuticals Q1 Earnings Call Highlights

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported first-quarter 2026 total revenue of $268 million, and executives said the company is maintaining its full-year outlook as it advances a pipeline led by remlifanserin in Alzheimer's disease psychosis and trofinetide in Japan.

Chief Executive Officer Cath...

Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of -54.23% and -5.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. Acadia delivered a solid first quarter of 2026 with total revenues of...

Insider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells 3,506 Shares of Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) EVP Mark Schneyer sold 3,506 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $21.79, for a total value of $76,395.74. Following the transaction, the executive vice president directly owned...

James Kihara Sells 1,332 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 1,332 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $29,024.28. Following the completion of the sale, the...

ImmunityBio to Report Q1 Earnings: What's in the Cards?

IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.

IQVIA Set to Report Q1 Earnings: Here's What You Should Know

IQV heads into Q1 earnings release with steady growth expectations, driven by AI-backed solutions, strong bookings and rising pharma demand.

Guardian Pharmacy Services to Report Q1 Earnings: What's in the Cards?

GRDN heads into Q1 earnings with revenues seen at $329.7M, as growth trends, vaccine volumes and IRA pricing impacts take center stage.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

ACAD
Acadia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACAD News

ACADAcadia Pharmaceuticals Inc